Cefquinome is a new injectable aminothiazolyl cephalosporin derivative. It is stable against chromosomally and plasmid-encoded I8-lactamases and has a broad antibacterial spectrum. Staphylococcus aureus, streptococci, Pseudomonas aeruginosa, and members of the family Enterobacteriaceae (Escherichia coli, Salmonella spp., Klebsiella spp., Enterobacter spp., Citrobacter spp., and Serratia marcescens) are inhibited at low concentrations. Cefquinome is also active against many strains of methicillin-resistant staphylococci and enterococci. Its in vitro activity against gram-negative anaerobes is very limited. The high in vitro activity of cefquinome is reflected by its high in vivo efficacy against experimental septicemia due to different gram-positive and gram-negative bacteria. We studied the pharmacokinetic properties of cefquinome in mice, dogs, pigs, and calves. After single parenteral administrations, cefquinome displayed high peak levels, declining with half-lives of about 0.5, 0.9, 1.2, and 1.3 h, respectively. The areas under the concentration-time curve determined for dogs and mice showed linear correlations to the given doses. In dogs the urinary recovery was more than 70% within 24 h of dosing.

HR 756 is a new cephalosporin derivative suitable for parenteral use. The compound possesses an unusally broad spectrum of antibacterial activity especially against gram-negative bacteria. Besides Escherichia coli, Salmonella, Klebsiella, indole-negative Proteae and other species also indol-positive Proteae, Serratia marcescens, Enterobacter and many Pseudomonas aeruginosa strains are inhibited by this compound. HR 756 is stable to most of the beta-lactamases produced by gram-negative organisms. Tests on different infection models also provided evidence of the high efficacy of HR 756 in vivo.

No abstract

No abstract

No abstract